Home LiteratureArticle Details
PMID: 24341879 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Comment

Requirement of NK cells for selective A2A receptor blockade to suppress CD73+ tumor metastasis.

Immunotherapy ·Vol. 6 ·No. 1 ·2014-00-00 ·Pages 19-21

Qin L, Thompson LF, Kuzel TM, Zhang B

Abstract

Evaluation of: Beavis PA, Divisekera U, Paget C et al. Blockade of A2A receptors potently suppresses the metastasis of CD73(+) tumors. Proc. Natl Acad. Sci. USA 110(36), 14711-14716 (2013). CD73 is becoming an emerging therapeutic target for the prevention of tumor growth and metastasis. However, the mechanism by which CD73 promotes tumor metastasis is unclear. Beavis et al. evaluated the efficacy of A2A and A2B adenosine receptor antagonists in inhibiting the metastasis of tumors expressing CD73, either endogenously or ectopically. They demonstrate distinct mechanisms whereby A2A versus A2B adenosine receptors could contribute to CD73(+) tumor metastasis. As A2Areceptor (R)/A2BR antagonists have been tested in clinical trials in other disease settings, this study highlights the potential therapeutic application of an A2AR/A2BR blockade strategy for treatment of CD73(+) metastatic tumors.

MeSH Terms
5'-Nucleotidase/immunology Animals Humans Killer Cells, Natural/immunology Neoplasms, Experimental/immunology Receptor, Adenosine A2A/immunology
Chemicals
Receptor, Adenosine A2A 5'-Nucleotidase
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Qin Lei
Robert H. Lurie Comprehensive Cancer Center, Department of Medicine-Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, 300 E Superior Street-Tarry 13-705, Chicago, IL 60611, USA.
Thompson Linda F
Kuzel Timothy M
Zhang Bin
References (20)
20 references, click to expand
  1. Ecto-enzyme and signaling functions of lymphocyte CD73.
    Immunol Rev. 1998 Feb;161:95-109 PMID: 9553767
  2. Adenosine receptors in regulation of dendritic cell differentiation and function.
    Blood. 2008 Sep 1;112(5):1822-31 PMID: 18559975
  3. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells.
    J Immunol. 2013 Oct 15;191(8):4165-73 PMID: 24043904
  4. Extracellular adenosine triphosphate and adenosine in cancer.
    Oncogene. 2010 Sep 30;29(39):5346-58 PMID: 20661219
  5. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.
    Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1547-52 PMID: 20080644
  6. Adenosine A2B receptor blockade slows growth of bladder and breast tumors.
    J Immunol. 2012 Jan 1;188(1):198-205 PMID: 22116822
  7. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice.
    J Clin Invest. 2011 Jun;121(6):2371-82 PMID: 21537079
  8. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells.
    J Immunol. 2011 Dec 1;187(11):6120-9 PMID: 22039302
  9. A2A adenosine receptor protects tumors from antitumor T cells.
    Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7 PMID: 16916931
  10. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
    Cancer Res. 2011 Apr 15;71(8):2892-900 PMID: 21292811
  11. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.
    Cancer Res. 2010 Mar 15;70(6):2245-55 PMID: 20179192
  12. CD73-deficient mice are resistant to carcinogenesis.
    Cancer Res. 2012 May 1;72(9):2190-6 PMID: 22396496
  13. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases.
    Nat Rev Drug Discov. 2008 Sep;7(9):759-70 PMID: 18758473
  14. CD73: a novel target for cancer immunotherapy.
    Cancer Res. 2010 Aug 15;70(16):6407-11 PMID: 20682793
  15. CD73: a potent suppressor of antitumor immune responses.
    Trends Immunol. 2012 May;33(5):231-7 PMID: 22487321
  16. Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis.
    Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5139-44 PMID: 23483055
  17. Opportunities and challenges for anti-CD73 cancer therapy.
    Immunotherapy. 2012 Sep;4(9):861-5 PMID: 23046227
  18. Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states.
    J Mol Med (Berl). 2013 Feb;91(2):165-72 PMID: 23292173
  19. ENTPD1/CD39 is a promising therapeutic target in oncology.
    Oncogene. 2013 Apr 4;32(14):1743-51 PMID: 22751118
  20. Physiological roles for ecto-5'-nucleotidase (CD73).
    Purinergic Signal. 2006 Jun;2(2):351-60 PMID: 18404475
Article Info
Journal
Immunotherapy
Abbr.
Immunotherapy
ISSN
1750-7448
DOI
10.2217/imt.13.154
Published
2014-00-00
Pages
19-21
Language
English
Region
England
NLM ID
101485158
PMCID
PMC3968679
Subset
IM
Grants
NCI NIH HHS · CA149669 · United States
NCI NIH HHS · P30 CA060553 · United States
NCI NIH HHS · R01 CA149669 · United States
NIAID NIH HHS · R01 AI018220 · United States
NIAID NIH HHS · AI18220 · United States
Corrections
CommentOn
PMID: 23964122
External Links
PubMed source DOI: 10.2217/imt.13.154 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2